David Mardle

David Mardle is a partner in Goodwin’s Technology and Life Sciences group and co-chair of Goodwin UK. With 20 years of experience advising on financings and M&A transactions in the life sciences and technology sectors, leveraging his significant M&A experience combined with his general corporate and capital markets expertise, David now concentrates his focus on representing emerging  companies providing counsel on corporate and capital markets transactions.

Prior to joining Goodwin in 2019, David was a partner at Taylor Wessing LLP.

David serves as secretary to Cambridge Network, a networking organization for business people and academics working in technology fields in the Cambridge area of the UK. The businesses and organizations that make up its membership are typical of those found in the “Cambridge Cluster” or Silicon Fen.

David is also a member of the working group of the British Venture Capital Association for the model documents for equity investment transactions.

Chambers and Partners UK (2025) ranks David in Band 1 for Private Equity: Venture Capital Investment and in Band 3 for Life Sciences: Transactional. Moreover, The Legal 500 UK (2025) lists David in its ‘Hall of Fame’ for Corporate and Commercial, and Venture Capital.

Client testimonials cite:

• “David provides exceptional service and advice.”
• “He’s extremely well known for working on high growth innovation companies."
• “David is highly specific and clear. He does great work.”
• “He is an excellent lawyer: commercial, savvy and available.”
• “We worked with Goodwin on the acquisition of our startup. David Mardle was a pleasure to work with – expert and knowledgeable as well as efficient. We felt in safe hands and his calm confidence made the deal much less stressful than it might have been.”

• “Standing Firm: Why Medtech Remains Robust During a Downturn,” MedTech Innovation News, September 2020